| Document |
Document Title |
|
WO/1992/003727A1 |
A process for determining the presence of an isothiazolone in a sample, comprises treating the sample with base and then with a phosphomolybdtungstic acid reagent, and observing and, if desired, measuring, the colour thus generated. The ...
|
|
WO/1991/016316A1 |
Chiral oxazolines having general formula (I) wherein R is C1 to C10 alkyl or phenyl and the R1 groups are independently hydrogen or C1 to C4 alkyl are prepared in substantially optically pure form by a process comprising the steps of (1)...
|
|
WO/1991/015479A1 |
Substituted pyrazoles, isoxazoles and isothiazoles of formula (I) are angiotensin II antagonists, and are useful in the treatment of hypertension, ocular hypertension and certain CNS disorders.
|
|
WO/1991/007395A1 |
The description relates to stabilised aqueous solutions of one or more 3-isothiazolinones of general formula (I) or (II) which contain at least 0.1 % wt. in relation to the entire solution of a 3-isothiazolinone, an organic and/or inorga...
|
|
WO/1991/005777A1 |
Single enantiomers of chiral sultams having general formula (I), where the R groups are independently hydrogen or C1 to C6 alkyl, and the R1 group is C1 to C20 alkyl, in substantially optically pure form are provided. The single enantiom...
|
|
WO/1990/015047A1 |
This invention is therapeutically useful 2-aminotetralins and pharmaceutically acceptable acid addition salts thereof of formula (I). These compounds are useful to treat central nervous system disorders, hypertension, diabetes, sexual im...
|
|
WO/1990/014330A1 |
A compound of formula (I), where Z is hydrogen or halogen, Q is COR1 or 5- or 6-membered aryl which may contain 1 or 2 heteroatoms selected from N, O or S and may be substituted or fused wherein R is hydrogen or C1-methyl (cis-configurat...
|
|
WO/1990/013549A1 |
Novel 2-substituted saccharin derivatives useful as proteolytic enzyme inhibitors, compositions containing the same for the treatment of degenerative diseases and method of use thereof.
|
|
WO/1990/013597A1 |
Disclosed are poly-methine compounds having formula (I), wherein R1 is an unsubstituted or substituted alkoxycarbonyl, cycloalkoxycarbonyl or aryloxycarbonyl radical; an unsubstituted or substituted carbamoyl radical; or an unsubstituted...
|
|
WO/1990/010630A1 |
[5(6)-(benzisoxa-, benzisothia- or indazol-3-yl)-1H-benzimidazol-2-yl] carbamates of formula (I) wherein R1 is hydrogen, C 1-4alkyl, halo, hydroxy or C1-4alkyloxy; R2 is C1-4alkyl; and X is O, S, SO, SO2 or NR3, said R3 being hydrogen, C...
|
|
WO/1990/005132A1 |
The invention relates to substituted allylamine derivatives and nontoxic salts thereof useful as a cholesterol-depressing agent and represented by general formula (I), [wherein A1 and A2 each represents a methine group, N, O or S; Q1 and...
|
|
WO/1990/002126A1 |
The present invention relates to hydantoin derivatives, represented by formula (I), and non-toxic salts, solvates and solvates of non-toxic salts thereof; wherein Q represents a mono- or a fused heterocyclic group which may be substitute...
|
|
WO/1990/000051A1 |
Non-peptidyl compounds characterized generally as ethereal N-terminal aminodiol derivatives of amino acids are useful as renin inhibitors for the treatment of hypertension. Compounds of particular interest are of formula (I), wherein X i...
|
|
WO/1990/000050A1 |
Non-peptidyl compounds characterized generally as aminoalkylaminocarbonyl aminodiol derivatives of amino acids are useful as renin inhibitors for the treatment of hypertension. Compounds of particular interest are of formula (I), wherein...
|
|
WO/1989/008107A1 |
Diamines and bismaleinimides of general formula (I) in which R1 and R2 each denote H-atom or together denote the group -OC-CH-=CH-CO-, Y1 and Y2 denote independently of each other O or S, and Het denotes a 5-membered heterocycle with 2 o...
|
|
WO/1989/006231A1 |
This invention concerns chemiluminescent moieties useful as labels in assays and immunoassays, and compositions and assay kits incorporating the moieties. The chemiluminescent moieties are of the type wherein attack by peroxide or molecu...
|
|
WO/1989/001934A1 |
The present invention relates to novel hydantoin derivatives, processes for producing said hydantoin derivatives, pharmaceutical compositions containing at least one of said hydantoin derivatives as aldose reductase inhibitors and novel ...
|
|
WO/1987/005898A2 |
Method for retarding plant growth by applying to the plant an effective amount of a malonic acid derivative compound. This invention also relates to novel malonic acid derivative compounds and processes for the preparation thereof.
|
|
WO/1987/005897A2 |
Malonic acid derivative compounds, processes for their preparation and their use for increasing crop yield.
|
|
WO/1987/003782A1 |
Herbicidal compounds of formula (I) in which, for example, X is Br, Cl or F; Y is Cl or Br, R2 is CHF2, R3 is CH3, R is lower alkyl and R1 is H, Na, lower alkyl or -SO2R.
|
|
WO/1987/000536A1 |
A curable compositon including a monomer having at least one curable acrylic functionality, an accelerator and optionally a free radical initiator, wherein the accelerator is a compound of formula (I), wherein R' is H or alkyl; when R' i...
|
|
WO/1986/007590A1 |
Polyhaloalkene compounds of formula (I), wherein X is sulfur, oxygen, nitrogen or methylene, Y1 and Y2 independently are fluorine, chlorine or bromine, Z is hydrogen or the same as Y1 or Y2, and n is 1-4; provided that: (A) when X is sul...
|
|
WO/1986/002552A1 |
A class of bicyclic benzenoid aminoalkylene ether and thioether compounds exhibiting pharmacological activity, including anti-secretory and anti-ulcerogenic activity, pharmaceutical compositions comprising these compounds, and methods fo...
|
|
WO/1985/005032A1 |
A class of benzocyclobutene aminoalkylene ether and thioether compounds exhibiting pharmacological activity, including anti-secretory and anti-ulcerogenic activity, pharmaceutical compositions comprising these compounds, and methods for ...
|
|
WO/1984/004247A1 |
A class of bicyclic benzenoid aminoalkylene ether and thioether compounds exhibiting pharmacological activity, including anti-secretory and anti-ulcerogenic activity, pharmaceutical compositions comprising these compounds, and methods fo...
|
|
WO/1984/004245A1 |
A class of naphthalene aminoalkylene ether and thioether compounds exhibiting pharmacological activity including anti-secretory and anti-ulcerogenic activity, pharmaceutical compositions comprising these compounds, and methods for the tr...
|
|
WO/1982/004048A1 |
Novel class of amidinourea and amidinothiourea compounds wherein the urea nitrogen atom is substituted by a heretocyclic alkylene group, and their use in pharmaceutical preparations which are useful for producing anti-ulcerogenic, antise...
|
|
WO/1982/004047A1 |
Novel class of heterocyclic amidinourea and heterocyclic amidinothiourea compounds wherein the heterocyclic substitution is at the 1-N urea nitrogen atom. These compounds exhibit pharmaceutical activity and may be incorporated into pharm...
|
|
JP7475049B2 |
The invention relates to alkoxybenzeno five- or six-member heterocyclic amines compounds as scheme I , in which the R1, R2 and R3 are consistent with the detailed description in the patent claim. The compounds can act as selective sphing...
|
|
JP2024513606A |
The present invention relates to formula (I) (wherein A, Z, L, R1,R2,R3,R4,R5and R33is defined in claim 1), or a pharmaceutically acceptable salt thereof. Compounds of formula (I) have utility as inhibitors of TEAD. The present compounds...
|
|
JP2024512340A |
The present invention relates to compounds, compositions, and methods for treating viral infections. In particular, entry inhibitor compounds are disclosed for the treatment of coronavirus infections, including SARS-CoV-1 and SARS-CoV-2 ...
|
|
JP2024510939A |
The present disclosure provides novel arylsulfonamide compounds as embodiments of the disclosure. The compounds are believed to be orexin receptor agonists, useful in treating diseases and conditions caused by decreased activity of orexi...
|
|
JP2024023301A |
The present invention provides novel compounds effective for controlling pests. The molecule of formula 1, as well as its N-oxides, agriculturally acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystalline...
|
|
JP2024012132A |
The present invention provides a photoactive compound, a photoresist composition containing the same, and a pattern forming method. [Solution] A photoactive compound containing an organic cation and an anion represented by the following ...
|
|
JP2024010022A |
The present invention provides a KRAS G12C inhibitor for treating, for example, lung cancer, pancreatic cancer, or colon cancer. The inhibitors are benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyrid...
|
|
JP2023552793A |
The present invention provides RXFP1 modulators for the treatment of heart failure, heart failure with preserved ejection fraction, heart failure with mildly reduced ejection fraction, heart failure with reduced ejection fraction, chroni...
|
|
JP2023179389A |
To provide a compound for treating and preventing diseases and conditions including heart failure, heart failure with a maintained ejection fraction, heart failure with a mildly reduced ejection fraction, heart failure with a reduced eje...
|
|
JP7398551B2 |
According to the present invention, it is possible to provide an actinic ray-sensitive or radiation-sensitive resin composition containing a resin of which a solubility in a developer changes by the action of an acid, a photoacid generat...
|
|
JP7397075B2 |
A process for preparing a nitrated compound, including the step of reacting a compound (A) including at least one substituted or unsubstituted aromatic or heteroaromatic ring, wherein the heteroaromatic ring includes at least one heteroa...
|
|
JP7387818B2 |
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...
|
|
JP2023162464A |
To provide a composition for water treatment that has good storage stability in liquid form and high sterilization performance, a water treatment method that uses the composition for water treatment, a production method of the compositio...
|
|
JP2023547235A |
The present invention provides a method for preparing 1,2-benzisothiazolin-3-one according to formula (I), comprising: (a) a 2-halogenbenzonitrile compound of general formula (II); i) alkali sulfide and/or alkali hydrogen sulfide, and (i...
|
|
JP7373014B2 |
Provided herein are compounds of formulae (I), (II), (III), (III´), (IV), (IV´) and (V):as KRAS G12C inhibitors for use in treating cancer, such as e.g. pancreatic, colorectal and lung cancer.Preferred compounds are e.g. benzoisothiazo...
|
|
JP7364258B2 |
The invention provides a small molecule compound of a NO donor, characterized in that the small molecule compound of the NO donor is a compound shown in the following structural formula I or a stereoisomer, a geometric isomer, a tautomer...
|
|
JP7358627B2 |
The present invention provides: an actinic ray-sensitive or radiation-sensitive resin composition containing (A) a resin in which polarity is increased due to acid activity, and (B) a compound which is represented by a specific general f...
|
|
JP2023136302A |
To provide a 3-aminobenzo[c]isothiazole-5-sulfonamide derivative as a novel compound, and a production method thereof.The invention provides a 3-aminobenzo[c]isothiazole-5-sulfonamide derivative represented by the general formula (3) in ...
|
|
JP2023533388A |
Disclosed herein are for the treatment of cancers such as glioblastoma, gastric cancer, colorectal cancer, pancreatic ductal adenocarcinoma (PDAC), and malignant pleural mesothelioma (MPM) Synthesis and use of covalent inhibitors that ar...
|
|
JP7310071B2 |
The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit t...
|
|
JP2023525909A |
The present invention relates to the formula (I) (In the formula, R1~R2as defined in the specification and claims). The compounds of formula (I) can be used as medicaments.
|
|
JP2023524684A |
The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of the PI3K-α enzyme using the compounds and compositions of the disclosure. The disclosure further relat...
|
